FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering
FDA Drug Safety Communication
A safety announcement by the FDA on the dangers of rapid discontinuation of opioid medication with patients who are physically dependent.
Read the article here.
